NOT FOR DISTRIBUTION
Header cover image

China Grand Pharmaceutical and Healthcare Holdings

Market Cap

HK$23.0b

Last Updated

2021/04/11 10:11 UTC

Data Sources

Company Financials +

Executive Summary

China Grand Pharmaceutical and Healthcare Holdings Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and nutrition products, and pharmaceutical raw materials. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has China Grand Pharmaceutical and Healthcare Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 512 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 512's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

2.2%

512

0.8%

HK Pharmaceuticals

-1.1%

HK Market


1 Year Return

32.0%

512

21.2%

HK Pharmaceuticals

28.6%

HK Market

Return vs Industry: 512 exceeded the Hong Kong Pharmaceuticals industry which returned 21.2% over the past year.

Return vs Market: 512 exceeded the Hong Kong Market which returned 28.6% over the past year.


Shareholder returns

512IndustryMarket
7 Day2.2%0.8%-1.1%
30 Day-0.5%0.7%-1.8%
90 Day1.7%10.0%3.4%
1 Year34.4%32.0%23.0%21.2%33.5%28.6%
3 Year35.0%29.4%-14.3%-19.1%4.0%-6.9%
5 Year353.0%334.2%79.2%62.4%48.7%23.7%

Long-Term Price Volatility Vs. Market

How volatile is China Grand Pharmaceutical and Healthcare Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is China Grand Pharmaceutical and Healthcare Holdings undervalued compared to its fair value and its price relative to the market?

12.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 512 (HK$6.47) is trading below our estimate of fair value (HK$7.43)

Significantly Below Fair Value: 512 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 512 is poor value based on its PE Ratio (12.4x) compared to the HK Pharmaceuticals industry average (12x).

PE vs Market: 512 is poor value based on its PE Ratio (12.4x) compared to the Hong Kong market (11.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 512's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 512 is overvalued based on its PB Ratio (2x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is China Grand Pharmaceutical and Healthcare Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

23.5%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 512's forecast earnings growth is above the savings rate (1.5%).

Earnings vs Market: Insufficient data to determine if 512's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 512's revenue (23.5% per year) is forecast to grow faster than the Hong Kong market (13.3% per year).

High Growth Revenue: 512's revenue (23.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 512's Return on Equity is forecast to be high in 3 years time (27%)


Past Performance

How has China Grand Pharmaceutical and Healthcare Holdings performed over the past 5 years?

41.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 512 has high quality earnings.

Growing Profit Margin: 512's current net profit margins (28.2%) are higher than last year (17.5%).


Past Earnings Growth Analysis

Earnings Trend: 512's earnings have grown significantly by 41.8% per year over the past 5 years.

Accelerating Growth: 512's earnings growth over the past year (55.6%) exceeds its 5-year average (41.8% per year).

Earnings vs Industry: 512 earnings growth over the past year (55.6%) exceeded the Pharmaceuticals industry 2.7%.


Return on Equity

High ROE: 512's Return on Equity (15.7%) is considered low.


Financial Health

How is China Grand Pharmaceutical and Healthcare Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 512's short term assets (HK$5.3B) exceed its short term liabilities (HK$4.3B).

Long Term Liabilities: 512's short term assets (HK$5.3B) exceed its long term liabilities (HK$1.3B).


Debt to Equity History and Analysis

Debt Level: 512's debt to equity ratio (20.9%) is considered satisfactory.

Reducing Debt: 512's debt to equity ratio has reduced from 213.7% to 20.9% over the past 5 years.

Debt Coverage: 512's debt is well covered by operating cash flow (56.8%).

Interest Coverage: 512's interest payments on its debt are well covered by EBIT (16.2x coverage).


Balance Sheet


Dividend

What is China Grand Pharmaceutical and Healthcare Holdings's current dividend yield, its reliability and sustainability?

1.70%

Current Dividend Yield


Upcoming Dividend Payment

TodayApr 11 2021Ex Dividend DateJun 08 2021Dividend Pay DateJun 23 202115 days from Ex DividendBuy in the next 57 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 512's dividend (1.7%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.96%).

High Dividend: 512's dividend (1.7%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 512 has been paying a dividend for less than 10 years.

Growing Dividend: 512's dividend payments have increased, but the company has only paid a dividend for 2 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (21.1%), 512's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.6yrs

Average board tenure


CEO

Yan Shao (57 yo)

12.5yrs

Tenure

HK$2,539,000

Compensation

Dr. Yan Shao has been the Chief Executive Officer at China Grand Pharmaceutical and Healthcare Holdings Ltd. (formerly, China Grand Pharmaceutical and Healthcare Holdings Limited (formerly known as MAXX Bi...


CEO Compensation Analysis

Compensation vs Market: Yan's total compensation ($USD326.41K) is below average for companies of similar size in the Hong Kong market ($USD720.55K).

Compensation vs Earnings: Yan's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: 512's board of directors are seasoned and experienced ( 12.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.1%.


Top Shareholders

Company Information

China Grand Pharmaceutical and Healthcare Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Grand Pharmaceutical and Healthcare Holdings Limited
  • Ticker: 512
  • Exchange: SEHK
  • Founded: 1995
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$22.966b
  • Shares outstanding: 3.55b
  • Website: https://www.chinagrandpharm.com

Number of Employees


Location

  • China Grand Pharmaceutical and Healthcare Holdings Limited
  • The Center
  • Units 3302
  • Central
  • Hong Kong

Listings


Biography

China Grand Pharmaceutical and Healthcare Holdings Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices,...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 10:11
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.